EU issues Erbitux, Cymbalta decisions

The EMEA's Committee for Medicinal Products for Human Use (CHMP) issued a number of recommendations this week. Many, such as Merck received good news, but Eli Lilly was not so lucky. Here's a brief roundup:

  • GlaxoSmithKline received a positive recommendation to add a stronger version to its line-up of the over-the-counter obesity med, Alli (orlistat).
  • The committee supported Roche's application to extend the indication of Pegasys in combination with ribavirin to the treatment of hepatitis C.   
  • The panel backed wider approval of Sepracor's Lunivia for insomnia.
  • Celgene's Vidaza (azacitidine) received a position opinion for wider indication for the treatment of myelodysplastic syndromes and acute myeloid leukaemia in adults.
  • Merck KGaA received a positive recommendation for the indication of Erbitux for head and neck cancer.
  • Eli Lilly and Boehringer Ingelheim's Cymbalta was given a negative rating for the treatment of fibromyalgia.

- check out the CHMP release for a complete list

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.